REFERENCES

1. Strand DS, Kim D and Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut Liver 2017; 11: 27-37.
2. Ying J, Li LC, Wu CY, Yu ZW and Kan LD. The status of proton pump inhibitor use: a prescription survey of 45 hospitals in China. Rev Esp Enfer Dig 2019; 111: 738-743.
3. Pasina L, Novella A, Elli C, Nobili A and Ianes A. Overuse of proton pump inhibitors in nursing homes: an Italian multicenter observational study. Pharmacoepidemiol Drug Saf 2020; 29: 461-466.
4. Haastrup PF, Thompson W, Søndergaard J and Jarbøl DE. Side effects of long-term proton pump inhibitor use: a review. Basic Clin Pharm Toxicol 2018; 123: 114-121.
5. Perry IE, Sonu I, Scarpignato C, Akiyama J, Hongo M and Vega KJ. Potential proton pump inhibitor-related adverse effects. Ann N Y Acad Sci 2020; https://doi.org/10.1111/nyas.14428.
6. Rameau A, Andreadis K, Bayoumi A, Kaufman M and Belafsky P. Side effects of proton pump inhibitors: what are patients’ concerns? J Voice 2020; https://doi.org/10.1016/j.jvoice.2020.01.018.
7. Savarino V, Marabotto E, Furnari M, Zingone F, Zentilin P and Savarino E. Latest insights into the hot question of proton pump inhibitor safety - a narrative review. Dig Liver Dis 2020; 52: 842-852.
8. Badiola N, Alcalde V, Pujol A, Münter LM, Multhaup G, Lleó A, et al. The proton-pump inhibitor lansoprazole enhances amyloid beta production. PLoS One 2013; 8: e58837.
9. Lam JR, Schneider JL, Zhao W and Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. Jama 2013; 310: 2435-42.
10. Akter S, Hassan MR, Shahriar M, Akter N, Abbas MG and Bhuiyan MA. Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software. Alzheimer’s Research & Therapy 2015; 7: 79.
11. Haenisch B, von Holt K, Wiese B, Prokein J, Lange C, Ernst A, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. European Archives of Psychiatry & Clinical Neuroscience 2015; 265: 419-28.
12. Gomm W, von Holt K, Thome F, Broich K, Maier W, Fink A, et al. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. JAMA Neurology 2016; 73: 410-6.
13. Tai SY, Chien CY, Wu DC, Lin KD, Ho BL, Chang YH, et al. Risk of dementia from proton pump inhibitor use in Asian population: A nationwide cohort study in Taiwan. PLoS ONE [Electronic Resource] 2017; 12: e0171006.
14. Batchelor R, Gilmartin JF, Kemp W, Hopper I and Liew D. Dementia, cognitive impairment and proton pump inhibitor therapy: A systematic review. Journal of Gastroenterology & Hepatology 2017; 32: 1426-1435.
15. Chen LY, Lin HJ, Wu WT, Chen YC, Chen CL, Kao J, et al. Clinical Use of Acid Suppressants and Risk of Dementia in the Elderly: A Pharmaco-Epidemiological Cohort Study. International Journal of Environmental Research & Public Health [Electronic Resource] 2020; 17: 09.
16. Zhang Y, Liang M, Sun C, Song EJ, Cheng C, Shi T, et al. Proton pump inhibitors use and dementia risk: a meta-analysis of cohort studies. Eur J Clin Pharmacol 2020; 76: 139-147.
17. Cooksey R, Kennedy J, Dennis MS, Escott-Price V, Lyons RA, Seaborne M, et al. Proton pump inhibitors and dementia risk: Evidence from a cohort study using linked routinely collected national health data in Wales, UK. PLoS ONE [Electronic Resource] 2020; 15: e0237676.
18. Wu CL, Lei WY, Wang JS, Lin CE, Chen CL and Wen SH. Acid suppressants use and the risk of dementia: A population-based propensity score-matched cohort study. PLoS ONE [Electronic Resource] 2020; 15: e0242975.
19. Park SK, Nam JH, Lee H, Chung H, Lee EK and Shin JY. Beyond uncertainty: Negative findings for the association between the use of proton pump inhibitors and risk of dementia. Journal of Gastroenterology & Hepatology 2019; 34: 2135-2143.
20. Gray SL, Walker RL, Dublin S, Yu O, Aiello Bowles EJ, Anderson ML, et al. Proton Pump Inhibitor Use and Dementia Risk: Prospective Population-Based Study. Journal of the American Geriatrics Society 2018; 66: 247-253.
21. Wod M, Hallas J, Andersen K, Garcia Rodriguez LA, Christensen K and Gaist D. Lack of Association Between Proton Pump Inhibitor Use and Cognitive Decline. Clinical Gastroenterology & Hepatology 2018; 16: 681-689.
22. Lai SW and Liao KF. Association Between Proton Pump Inhibitors Use and Dementia Risk. American Journal of Gastroenterology 2020; 115: 631.
23. Huang ST, Tseng LY, Chen LK, Peng LN and Hsiao FY. Does Long-Term Proton Pump Inhibitor Use Increase Risk of Dementia? Not Really! Results of the Group-Based Trajectory Analysis. Clinical Pharmacology & Therapeutics 2019; 106: 616-622.
24. Kumar R, Kumar A, Nordberg A, Langstrom B and Darreh-Shori T. Proton pump inhibitors act with unprecedented potencies as inhibitors of the acetylcholine biosynthesizing enzyme-A plausible missing link for their association with incidence of dementia. Alzheimer’s & Dementia 2020; 16: 1031-1042.
25. FDA. Data mining at FDA: white paper [on-line]. Available at https://www.fda.gov/science-research/data-mining/data-mining-fda-white-paper Accessed January 28, 2021.
26. Duggirala HJ, Tonning JM, Smith E, Bright RA, Baker JD, Ball R, et al. Use of data mining at the Food and Drug Administration. J Am Med Inform Assoc 2016; 23: 428-434.
27. Evans SJ, Waller PC and Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10: 483-486.
28. FDA. FDA adverse event reporting system (FAERS) quarterly data extract files [on-line]. Available at https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html Accessed January 28, 2021.
29. Xu H, Stenner SP, Doan S, Johnson KB, Waitman LR and Denny JC. MedEx: a medication information extraction system for clinical narratives. Journal of the American Medical Informatics Association 2010; 17: 19-24.
30. Wu B, Wu FB, Luo M, Qin Z and Xu T. Application of MedEx in FAERS drug names standardization. China J of Hosp Pharm 2019; 39: 1989-1992.
31. van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R and Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11: 3-10.
32. Evans SJ, Waller PC and Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiology & Drug Safety 2001; 10: 483-6.
33. Lochhead P, Hagan K, Joshi AD, Khalili H, Nguyen LH, Grodstein F, et al. Association Between Proton Pump Inhibitor Use and Cognitive Function in Women. Gastroenterology 2017; 153: 971-979.e4.
34. Taipale H, Tolppanen AM, Tiihonen M, Tanskanen A, Tiihonen J and Hartikainen S. No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer’s Disease. American Journal of Gastroenterology 2017; 112: 1802-1808.
35. Palleria C, Leporini C, Chimirri S, Marrazzo G, Sacchetta S, Bruno L, et al. Limitations and obstacles of the spontaneous adverse drugs reactions reporting: Two ”challenging” case reports. J Pharmacol Pharmacother 2013; 4: S66-72.